NSI-189, a New Experimental Nootropic

NSI-189 is a new investigational antidepressant, which is purported to work differently from existing antidepressants. Researchers suggest this drug may potentially help those who do not respond to conventional medications. Research is also ongoing for its cognitive-enhancing effects. However, NSI-189 failed in a recent clinical trial. Learn about all the research behind this drug. NSI-189 is an investigational drug being developed by Neuralstem Inc., a biopharmaceutical company. NSI-189 was studied in phase I and II clinical trials for the treatment of major depressive disorder. As of July 2017, NSI-189 has failed to meet effectiveness outcomes for depression in phase II trials [ 1 ]. According to the developer, NSI-189 is still currently in preclinical trials for a number of other conditions, including [ 2 ]: Cognitive impairment and radiation-induced cognitive impairments Diabetic neuropathy, a form of nerve damage caused by diabetes Ischemic stroke Angelman Syndrome (a genetic disorder that causes developmental disabilities and nerve-related symptoms) The mechanism of action of NSI-189 is not completely understood. Initial research suggests that this experimental drug may work by promoting neurogenesis, the growth of new nerve and brain cells. More specifically, NSI-189 appears to primarily affect the hippocampus, the part of the brain responsible for emotion, learning, and memory [ 3 ]. In a cell study using human cells derived from the hippocampus, NSI-189 stimulated neurogenesis. A study using mice also suggests that NSI-189 may promote neurogenesis in the hippocampus [ 3 ]. Potential Uses of NSI-189 NSI-189 is an experimental drug that has not been approved by the FDA. The safety and effectiveness of this drug are unknown. The following sections detail investigational uses of NSI-189, but there is insufficient evidence to support the use of NSI-189 for any of these conditions. The below sections are for informational purposes only and in […]

Spread the love

Leave a Reply